胰岛素生物相似药市场－全球产业规模、份额、趋势、机会和预测，按类型、疾病适应症类型、配销通路、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球胰岛素生物相似药市场规模为15.5亿美元，预计2030年将以7.3%的复合年增长率成长至23.7亿美元。胰岛素生物相似药是与已核准的参考胰岛素产品高度相似的生物製剂，具有可比较的品质、安全性和疗效，但由于其固有的生物学复杂性，并非完全相同。全球胰岛素生物相似药市场的主要成长动力来自于主要品牌胰岛素产品专利的到期，这为生物相似药进入市场提供了便利。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球胰岛素生物相似药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（速效生物相似药、长效生物相似药、预混型生物相似药）
  • 依疾病适应症类型（I型糖尿病、II型糖尿病）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 依最终使用者（医院、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美胰岛素生物相似药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲胰岛素生物相似药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胰岛素生物相似药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲胰岛素生物相似药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲胰岛素生物相似药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球胰岛素生物相似药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Pfizer Inc
• Novartis AG
• Boehringer Ingelheim GmbH
• Merck KGaA
• Sanofi SA
• Viatris Inc
• NOVO Nordisk A/S
• Intas Pharmaceuticals Ltd
• Sandoz International GmbH
• Fresenius Kabi AG

第十六章：策略建议

第17章调查会社について・免责事项

The Global Insulin biosimilars Market, valued at USD 1.55 Billion in 2024, is projected to experience a CAGR of 7.3% to reach USD 2.37 Billion by 2030. Insulin biosimilars are biological medicines highly similar to an already approved reference insulin product, demonstrating comparable quality, safety, and efficacy, though not being exact copies due to their inherent biological complexity. The global insulin biosimilars market is primarily supported by the expiration of patents for major branded insulin products, facilitating market entry for biosimilar alternatives.

Key Market Drivers

The increasing global burden of diabetes stands as a fundamental driver for the insulin biosimilars market. As more individuals are diagnosed with diabetes worldwide, the demand for insulin therapies inherently expands, necessitating a broader and more accessible supply of treatment options. This chronic condition requires lifelong management, ensuring a continuous and growing patient pool reliant on insulin. According to the International Diabetes Federation, December 2023, IDF Diabetes Atlas 11th Edition, approximately 589 million adults globally were living with diabetes, a number projected to reach 853 million by 2050.

Key Market Challenges

The stringent and complex regulatory approval pathway represents a significant impediment to the growth of the global insulin biosimilars market. This pathway demands extensive clinical data to confirm high similarity to reference products, which escalates development costs and extends timelines for market entry. The substantial investment required to navigate these rigorous processes directly deters potential manufacturers from initiating or continuing biosimilar development.

Key Market Trends

Advancements in interchangeability designations significantly impact insulin biosimilar adoption by streamlining pharmacy-level substitution. This regulatory status allows pharmacists to dispense an interchangeable biosimilar for its reference product without prior physician approval, subject to state laws. Such a designation builds confidence among healthcare providers and patients regarding comparable safety and efficacy, facilitating broader market acceptance. According to a study published in JAMA in April 2025, the market share for insulin glargine-yfgn, an interchangeable biosimilar, increased by 7.03 percentage points in states with less restrictive substitution laws compared to more restrictive ones after its launch.

Key Market Players

• Pfizer Inc
• Novartis AG
• Boehringer Ingelheim GmbH
• Merck KGaA
• Sanofi S.A
• Viatris Inc
• NOVO Nordisk A/S
• Intas Pharmaceuticals Ltd
• Sandoz International GmbH
• Fresenius Kabi AG

Report Scope:

In this report, the Global Insulin biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insulin biosimilars Market, By Type:

• Rapid Acting biosimilars
• Long Acting biosimilars
• Premixed Acting biosimilars

Insulin biosimilars Market, By Disease Indication Type:

• Type I Diabetes
• Type II Diabetes

Insulin biosimilars Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Insulin biosimilars Market, By End user:

• Hospitals
• Ambulatory Surgical Centers
• Others

Insulin biosimilars Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Insulin biosimilars Market.

Available Customizations:

Global Insulin biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Insulin biosimilars Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars)
  • 5.2.2. By Disease Indication Type (Type I Diabetes, Type II Diabetes)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By End user (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Insulin biosimilars Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Indication Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Insulin biosimilars Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Indication Type
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Insulin biosimilars Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Indication Type
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Insulin biosimilars Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Indication Type
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By End user

7. Europe Insulin biosimilars Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Indication Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Insulin biosimilars Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Indication Type
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By End user
  • 7.3.2. France Insulin biosimilars Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Indication Type
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Insulin biosimilars Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Indication Type
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Insulin biosimilars Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Indication Type
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Insulin biosimilars Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Indication Type
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By End user

8. Asia Pacific Insulin biosimilars Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Indication Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Insulin biosimilars Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Indication Type
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By End user
  • 8.3.2. India Insulin biosimilars Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Indication Type
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Insulin biosimilars Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Indication Type
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Insulin biosimilars Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Indication Type
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Insulin biosimilars Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Indication Type
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By End user

9. Middle East & Africa Insulin biosimilars Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Indication Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Insulin biosimilars Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Indication Type
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Insulin biosimilars Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Indication Type
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Insulin biosimilars Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Indication Type
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By End user

10. South America Insulin biosimilars Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Indication Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Insulin biosimilars Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Indication Type
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Insulin biosimilars Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Indication Type
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Insulin biosimilars Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Indication Type
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Insulin biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Boehringer Ingelheim GmbH
• 15.4. Merck KGaA
• 15.5. Sanofi S.A
• 15.6. Viatris Inc
• 15.7. NOVO Nordisk A/S
• 15.8. Intas Pharmaceuticals Ltd
• 15.9. Sandoz International GmbH
• 15.10. Fresenius Kabi AG

16. Strategic Recommendations

17. About Us & Disclaimer